DUAG-1: Comparative trial. Citalopram (40 mg/d) versus clomipramine (150 mg/d), 5 weeks, in depression. N = 102. Inpatients. 1980-84
DUAG-2: Comparative trial. Paroxetine (30 mg/d) versus clomipramine (150 mg/d), 6 weeks, in depression. N = 120. Inpatients. 1985-87.
DUAG-3: Comparative trial. Moclobemide (300 mg/d) versus clomipramine (150 mg/d), 6 weeks, in depression. N = 115. Inpatients. 1987-90.
DUAG-4: Dose-effect study of clomipramine in depression; five fixed dose levels (25, 50, 75, 125, 200 mg/d) for 6 weeks. N = 151. Inpatients. 1990-94.
DUAG-5: Comparative trial of prophylactic effect of citalopram versus clomipramine versus placebo in unipolar depression. 2-4 years. In- and outpatients were followed over a period of 7 - 15 months before treatment discontinuation and inclusion in the prophylaxis study. Recruitment started 1997 and the last follow-up was completed by the end of 2006 with the inclusion of only 59 prophylaxis patients.
DUAG-6: Comparative trial of prophylactic effect of lamotrigine versus lithium in bipolar disorder. 2 years, non-blind, randomised. In- and outpatients. Recruitment started in 2000 and was completed in 2006 after inclusion of 155 patients.
DUAG-7: Relapse prevention in patients with major depression treated with electroconvulsive therapy comparing a fixed dose range of escitalopram with a fixed dose of nortriptyline. A randomised controlled 6 month double-blind study. Recruitment started in 2009.
|
print